---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-087464"
form_type: "8-K"
ticker: "REPL"
cik: "0001737953"
company_name: "Replimune Group, Inc."
filed_at: "2025-09-04T23:59:59+00:00"
generated_at: "2026-05-17T08:19:44.980034+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Replimune schedules Type A meeting with FDA to discuss RP1 CRL; program viability at risk

## Summary
- FDA Type A meeting scheduled to discuss CRL for RP1 BLA in advanced melanoma; briefing submitted with additional analysis.
- CEO states without accelerated approval, RP1 program in advanced melanoma, including phase 3 confirmatory trial, will not be viable.
- Stockholders voted against amending 2018 Omnibus Incentive Compensation Plan (26.97M for, 35.49M against).
- All director nominees elected; PwC ratification and say-on-pay proposals approved by stockholders.

## SEC filing metadata
- accession: 0001104659-25-087464
- form_type: 8-K
- ticker: REPL
- cik: 0001737953
- company_name: Replimune Group, Inc.
- filed_at: 2025-09-04T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 5.07, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737953/000110465925087464/0001104659-25-087464-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737953/000110465925087464/tm2525185d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-087464
- JSON: https://secwatch.observer/filing/0001104659-25-087464.json
- Plain text: https://secwatch.observer/filing/0001104659-25-087464.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.